Avalon GloboCare (NASDAQ:ALBT – Get Free Report) posted its quarterly earnings data on Monday. The company reported $0.46 earnings per share (EPS) for the quarter, FiscalAI reports.
Avalon GloboCare Stock Up 13.5%
ALBT stock opened at $0.57 on Tuesday. The company has a market cap of $2.42 million, a price-to-earnings ratio of -0.16 and a beta of -0.24. Avalon GloboCare has a twelve month low of $0.42 and a twelve month high of $5.28. The business has a 50 day moving average price of $0.76 and a two-hundred day moving average price of $1.43.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Avalon GloboCare in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.
About Avalon GloboCare
Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.
Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.
Read More
Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.
